Peter W. AndrewsUri Ben-DavidNissim BenvenistyPeter CoffeyKevin EgganBarbara B. KnowlesAndras NagyMartin PeraBenjamin ReubinoffPeter J. Rugg-GunnGlyn N. StaceyUniversity of SheffieldBroad InstituteHebrew University of JerusalemUCL Institute of OphthalmologyUniversity of California, Santa BarbaraHarvard UniversityHarvard Stem Cell InstituteJackson LaboratoryMahidol UniversityMount Sinai Hospital of University of TorontoMonash UniversityUniversity of MelbourneThe Florey Institute of Neuroscience and Mental HealthWalter and Eliza Hall Institute of Medical ResearchHadassah University Medical CentreThe Babraham InstituteWellcome Trust - Medical Research Council Cambridge Stem Cell InstituteMedicines and Health Care products Regulatory Agency2018-12-212019-03-142018-12-212019-03-142017-07-11Stem Cell Reports. Vol.9, No.1 (2017), 1-4221367112-s2.0-85021993873https://repository.li.mahidol.ac.th/handle/123456789/41846© 2017 Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyConference PaperSCOPUS10.1016/j.stemcr.2017.05.029